Assessment of the CHA\textsubscript{2}DS\textsubscript{2}-VASc Score for the Prediction of Death in Elderly Patients With Coronary Artery Disease and Atrial Fibrillation

Yangxun Wu\textsuperscript{1,2†}, Guanyun Wang\textsuperscript{1,2†}, Lisha Dong\textsuperscript{1†}, Liu'an Qin\textsuperscript{1,2}, Jian Li\textsuperscript{2}, Hengming Yan\textsuperscript{1}, Wenjie Guo\textsuperscript{2}, Xiaodong Feng\textsuperscript{2}, Yuting Zou\textsuperscript{1,2}, Ziqian Wang\textsuperscript{1,2}, Rina Du\textsuperscript{1}, Yuxiao Zhang\textsuperscript{2}, Jing Ma\textsuperscript{2} and Tong Yin\textsuperscript{1,2}∗

\textsuperscript{1}Institute of Geriatrics, National Clinical Research Center for Geriatric Diseases, 2nd Medical Center, Medical School of Chinese People’s Liberation Army and Chinese People’s Liberation Army General Hospital, Beijing, China. \textsuperscript{2}Department of Cardiology, 1st Medical Center, Medical School of Chinese PLA and Chinese PLA General Hospital, Beijing, China

\textbf{Purpose:} Coronary artery disease (CAD) and atrial fibrillation (AF) often coexist and lead to a much higher risk of mortality in the elderly population. The aim of this study was to investigate whether the CHA\textsubscript{2}DS\textsubscript{2}-VASc score could predict the risk of death in elderly patients with CAD and AF.

\textbf{Methods:} Hospitalized patients aged \(\geq 65\) years with a diagnosis of CAD and AF were recruited consecutively. Patients were divided into 5 groups according to the CHA\textsubscript{2}DS\textsubscript{2}-VASc score (\(\leq 2\), =3, =4, =5, and \(\geq 6\)). At least a 1-year follow-up was carried out for the assessment of all-cause death.

\textbf{Results:} A total of 1,579 eligible patients were recruited, with 582 all-cause deaths (6.86 per 100 patient-years) occurring during a follow-up of at least 1 year. With the increase in the CHA\textsubscript{2}DS\textsubscript{2}-VASc score, the 1-year and 5-year survival rate decreased (96.4% vs. 95.7% vs. 94.0% vs. 86.5% vs. 85.7%, respectively, \(P < 0.001\); 78.4% vs. 68.9% vs. 64.6% vs. 55.5% vs. 50.0%, respectively, \(P < 0.001\)). Compared with the patients with CHA\textsubscript{2}DS\textsubscript{2}-VASc score <5, for patients with CHA\textsubscript{2}DS\textsubscript{2}-VASc score \(\geq 5\), the adjusted hazard ratio for death was 1.78 (95% CI: 1.45–2.18, \(P < 0.001\)). The predictive values of the CHA\textsubscript{2}DS\textsubscript{2}-VASc score \(\geq 5\) for in-hospital (C-index = 0.66, 95% CI: 0.62–0.69, \(P < 0.001\)), 1-year (C-index = 0.65, 95% CI: 0.63–0.67, \(P < 0.001\)) and 5-year (C-index = 0.60, 95% CI: 0.59–0.61, \(P < 0.001\)) death were in comparable.

\textbf{Conclusion:} In elderly patients with concomitant CAD and AF, the CHA\textsubscript{2}DS\textsubscript{2}-VASc score can be used to predict death with moderate accuracy.

\textbf{Keywords:} elderly, atrial fibrillation, coronary artery disease, death, CHA\textsubscript{2}DS\textsubscript{2}-VASc score

\textbf{INTRODUCTION}

Coronary artery disease (CAD) is the most common cardiovascular disease, while atrial fibrillation (AF) is the most common cardiac arrhythmia (1). The prevalence of both CAD and AF increases monotonically with age (2, 3). CAD and AF often coexist and interact with each other (4). CAD is a leading cause of morbidity and mortality in elderly adults (5). Elderly patients are more likely than...
their younger counterparts to present with comorbidities (6–9), contributing to worse outcomes. Patients with AF are relatively older and have higher risk of stroke, which may contribute to increased mortality (10–16). Furthermore, AF is a well-established marker of poor short- and long-term prognosis in patients with acute myocardial infarction (AMI) (11, 12, 17, 18) and is associated with a large increase in overall mortality (15, 19). Therefore, the coexistence of CAD and AF might lead to a much higher risk of mortality in the elderly population.

The CHA₂DS₂-VASc score [congestive heart failure, hypertension, age ≥75 years (doubled), diabetes, stroke/transient ischemic attack/thromboembolism (doubled), vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), age 65–74 years, sex category (female)] has been used for the assessment of thromboembolic (TE) risk and the guidance of antithrombotic treatment in patients with AF (20). In addition, this simple and well-established scoring system has been shown to predict the risk for other conditions beyond its original designations (20–26).

In the presence of comorbidities of CAD and AF, advancing age further elevates the risk of TE complications and death. Evaluating the risk of death from TE in an elderly population with CAD and AF is important, because a competing-risk setting taking careful consideration of the interplay between the mortality of elderly individuals with CAD and AF, and mortality of ischemic stroke/TE is needed to provide meaningful risk assessments. However, how to assess the relationship between the mortality of ischemic stroke/TE and the high mortality of the elderly population is still unclear. Therefore, we aimed to evaluate whether the CHA₂DS₂-VASc score can predict the risk of death in elderly CAD and AF patients and be used as an indicator of treatment and prognosis.

METHODS

Patients
From January 2010 to December 2017, patients aged ≥65 years with a diagnosis of both CAD and AF who were hospitalized in the Department of Cardiology, Chinese PLA General Hospital, were recruited consecutively. This study complied with the Declaration of Helsinki and was approved by the institutional ethics committee of the General Hospital of the People’s Liberation Army. CAD was defined as stable coronary artery disease (SCAD, including stable angina, previous myocardial infarction and ischemic cardiomyopathy) and acute coronary syndrome (ACS, including unstable angina and acute myocardial infarction). AF was defined as an irregular rhythm recorded in a standard 12-lead electrocardiogram, including discrete P waves and their replacement with irregular chaotic oscillatory atrial activity (F waves) in the setting of irregular QRS complexes. Body mass index (BMI) was categorized according to the distribution of BMI among the patients and the WHO criteria (27). In line with the epidemiological evidence, a BMI from 22 to <25 kg/m² was used as the reference group. On defining the different classification of HF, we summarized the left ventricular ejection fraction (LVEF) data of the included CAD and AF patients. Patients with HF were stratified into 3 groups according to the criteria that LVEF <40% represents heart failure with reduced ejection fraction (HFrEF), LVEF ≥50% represents heart failure with preserved ejection fraction (HfPeF), and LVEF ranges from 40 to 50 represents heart failure with mid-range ejection fraction (HFmrEF).

Data Collection, Follow-Up and Death Definitions

Baseline demographics and clinical characteristics in the hospital were extracted from the electronic health records system. The components of the CHA₂DS₂-VASc score were collected to retrospectively assess the risk of mortality. The CHA₂DS₂-VASc score was calculated as congestive heart failure (1 point), aged 65–74 years (1 point), hypertension (1 point), diabetes (1 point), vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque; 1 point), female sex (1 point), aged 75 years or older (2 points) and stroke/transient ischemic attack/thromboembolism (2 points) (28, 29).

Participants were followed-up until Dec 31st, 2019. The follow-up protocol included a combination of hospital medical record reviews, telephone contacts with patients or family members and death certificate reviews. All deaths were independently adjudicated in a blinded manner by 2 members of the event adjudication committee. All-cause death was classified using the tenth revision of the International Classification of Disease and confirmed through death certificates using personal identity card numbers. Cardiac death was defined as death attributable to fatal myocardial infarction, sudden cardiac death or stroke. Apart from cardiac death, non-cardiac death included deaths from malignancies, infections, respiratory, trauma/accidental or other non-vascular deaths. If the cause of death could not be determined from the available evidence, death was classified as undetermined.

Statistical Analysis

The patients were divided into CHA₂DS₂-VASc score groups (≤2, =3, =4, =5, and ≥6) according to whether they had died by the end of follow-up. Baseline demographic and clinical characteristics were summarized using medians and interquartile ranges (IQRs) for continuous measures and percentages for categorical measures. The comparison of the data was performed using the chi-square test for categorical variables and Mann–Whitney U-test for continuous variables. Univariate and multivariate Cox regression models were used to explore the risk factors associated with mortality. According to the CHA₂DS₂-VASc score, Kaplan–Meier curves with the log-rank test were used to compare survival. The calibration of the CHA₂DS₂-VASc score was assessed with the Hosmer–Lemeshow goodness-of-fit test (HL), which may determine the degree of agreement between the observed event rate and the predicted one over a series of scores. A significant value of P < 0.05 represents a lack of fit. The concordance index (C-index) was conducted to determine the discrimination of and the diagnostic value of the CHA₂DS₂-VASc score for death. All analysis were performed with the R 4.0.1 Statistical Package (the R foundation for Statistical Computing, Vienna, Austria) and SPSS v.24.0 (Statistical Package for Social Science; IBM, Chicago, IL, USA).
RESULTS

Baseline Characteristics

Follow-up data were available for 1,579 patients (with a total of 1,579 patients for 1-year and 910 for 5-year follow-up). The baseline characteristics according to the CHA2DS2-VASc score are shown in Table 1. The mean CHA2DS2-VASc score was 4.3 ± 1.6 (median 4.0, interquartile range 3.0–5.0). We divided the cohort into five quintiles based on the CHA2DS2-VASc score: ≤2 (n = 192), 3 (n = 327), 4 (n = 384), 5 (n = 326), and ≥6 (n = 350) (Figure 1). Patients with a higher CHA2DS2-VASc score were more likely to be women, older and with cardiovascular diseases, such as AMI and heart failure (HF). The proportion of patients with HF was 38.3% (602/1579) in the whole study. Among the patients with HF, LVEF data were retrieved in 581 patients, with 114 of HFrEF (19.6%), 81 of HFmrEF (13.9%) and 368 of HFpEF (66.4%). The rate of comorbidities, such as hypertension, diabetes, prior transient ischemic attack (TIA)/stroke, peripheral arterial disease (PAD), chronic kidney disease (CKD) and HF, increased with the increasing CHA2DS2-VASc score. In terms of treatment, diuretics, calcium channel blockers (CCBs) and renin angiotensin system inhibitors (RASIs) were used more frequently in elderly patients with AF and CAD with a higher CHA2DS2-VASc score (Table 1). The application of oral anticoagulants

| TABLE 1 | Baseline characteristics of elderly patients with CAD and AF according to the CHA2DS2-VASc score. |
|---|---|---|---|---|---|
| Characteristics | CHA2DS2-VASc ≤2 (n = 192) | CHA2DS2-VASc = 3 (n = 327) | CHA2DS2-VASc = 4 (n = 384) | CHA2DS2-VASc = 5 (n = 326) | CHA2DS2-VASc ≥6 (n = 350) |
| **Demographics** | | | | | |
| Age, yrs, median (IQR) | 72 (67–78) | 76 (71–81) | 77 (73–83) | 79 (75–84) | 80 (77–84) |
| Male (%), n | 179 (90.2) | 255 (78.4) | 207 (53.4) | 136 (41.0) | 146 (41.4) |
| BMI, kg/m², median (IQR) | 22 (22–27) | 24 (23–27) | 25 (23–27) | 25 (22–27) | 24 (22–27) |
| **Medical history, n (%)** | | | | | |
| Hypertension | 65 (33.9) | 239 (73.1) | 289 (75.3) | 273 (83.7) | 318 (90.9) |
| Diabetes | 4 (2.1) | 47 (14.4) | 106 (27.6) | 131 (40.2) | 195 (55.7) |
| Previous myocardial infarction | 2 (1.0) | 23 (7.0) | 47 (12.2) | 54 (16.6) | 71 (20.3) |
| Prior TIA/stroke | 0 (0.0) | 5 (1.5) | 51 (13.3) | 103 (31.6) | 276 (78.9) |
| Peripheral arterial disease | 3 (1.6) | 32 (9.8) | 73 (19.0) | 88 (27.0) | 134 (38.3) |
| COPD | 6 (3.1) | 10 (3.1) | 21 (5.5) | 11 (3.4) | 10 (2.9) |
| Hyperlipidemia | 46 (24.0) | 62 (19.0) | 74 (19.3) | 73 (22.4) | 90 (25.7) |
| Chronic kidney disease | 6 (3.1) | 26 (8.0) | 44 (11.5) | 42 (12.9) | 47 (13.4) |
| Liver disease | 16 (8.3) | 31 (9.5) | 35 (9.1) | 23 (7.1) | 31 (8.9) |
| Malignancy | 24 (12.5) | 30 (9.2) | 49 (12.8) | 41 (12.6) | 50 (14.3) |
| **Clinical presentation, n (%)** | | | | | |
| SCAD | 104 (54.2) | 188 (57.5) | 217 (66.5) | 171 (52.5) | 177 (50.6) |
| ACS | 88 (45.8) | 139 (42.5) | 167 (43.5) | 155 (47.5) | 173 (49.4) |
| Unstable angina | 87 (45.3) | 130 (39.8) | 144 (37.5) | 125 (38.3) | 121 (34.6) |
| Acute myocardial infarction | 1 (0.5) | 11 (3.4) | 27 (7.3) | 31 (9.5) | 54 (15.4) |
| Heart failure | 15 (7.8) | 54 (16.5) | 152 (39.6) | 159 (48.8) | 222 (63.4) |
| **In-hospital treatment, n (%)** | | | | | |
| Diuretic | 56 (29.2) | 150 (45.9) | 230 (69.9) | 217 (66.5) | 264 (75.4) |
| Statins | 162 (84.4) | 275 (84.1) | 315 (82.0) | 276 (84.7) | 297 (84.9) |
| CCB | 57 (29.7) | 192 (58.7) | 206 (56.3) | 187 (57.4) | 226 (64.6) |
| β-blockers | 147 (76.6) | 246 (75.2) | 298 (77.6) | 263 (80.7) | 272 (77.7) |
| RASI | 56 (29.2) | 187 (57.2) | 218 (65.8) | 207 (63.5) | 232 (66.3) |
| **Antiplatelet therapy** | | | | | |
| Aspirin | 162 (84.4) | 249 (76.1) | 289 (75.3) | 242 (74.8) | 259 (74.0) |
| P2Y12 receptor inhibitors | 126 (65.6) | 198 (60.6) | 237 (61.7) | 191 (58.6) | 224 (64.0) |
| **Anticoagulation** | | | | | |
| Warfarin | 26 (13.5) | 59 (18.0) | 68 (17.7) | 59 (18.1) | 54 (15.4) |
| NOACs | 28 (14.6) | 42 (12.8) | 46 (12.0) | 40 (12.3) | 29 (8.3) |
| Amiodarone | 64 (33.3) | 96 (29.4) | 83 (21.6) | 79 (24.2) | 98 (28.0) |
| PCI with drug-eluting stent | 24 (12.5) | 36 (11.0) | 50 (13.0) | 30 (9.2) | 30 (8.6) |

Data are presented as the median (IQR), n (%), or n/N (%). CAD, Coronary artery disease; AF, Atrial fibrillation; BMI, Body mass index; TIA, Transient ischemic attack; COPD, Chronic obstructive pulmonary disease; SCAD, Stable coronary artery disease; ACS, Acute coronary syndrome; CCB, Calcium channel blocker; RASI, Renin angiotensin system inhibitors; NOACs, Nonvitamin K antagonist oral anticoagulants; PCI, Percutaneous coronary intervention.
(OACs) and oral antiplatelets (aspirin and P2Y₁₂ inhibitors) in all patients were 27.1% and 83.3%, respectively. With the increase of CHA₂DS₂-VASc score, no significant difference was found for the proportion of patients administrated with OACs (CHA₂DS₂-VASc score ≤2: 27.1%, score = 3: 28.4%, score = 4: 29.2%, score = 5: 27.3%, and score ≥6: 23.4%, \( P = 0.475 \)) or oral antiplatelet (score ≤2: 85.9%, score = 3: 81.3%, score = 4: 81.8%, score = 5: 82.8%, and score ≥6: 85.7%, \( P = 0.404 \)).

**Association Between CHA₂DS₂-VASc Score and Mortality**

A total of 582 patients died, with a mortality of 6.86 per 100 patient-years. The causes of death were cardiovascular in 152 patients (26.1%), non-cardiovascular in 247 patients (42.5%) and undetermined in 183 patients (31.4%). The in-hospital, 1-year and 5-year all-cause mortality were 3.0%, 8.7%, and 24.4%, respectively, and higher CHA₂DS₂-VASc scores were associated with a significantly higher mortality (Figure 2). The survival rate according to Kaplan–Meier analysis suggested that with the increase in the CHA₂DS₂-VASc score, the 1-year and 5-year survival rates decreased (96.4% vs. 95.7% vs. 94.0% vs. 86.5% vs. 85.7%, respectively, \( P < 0.001 \); 78.4% vs. 68.9% vs. 64.6% vs. 55.5% vs. 50.0%, respectively, \( P < 0.001 \)) (Figure 3).

Compared with the patients with CHA₂DS₂-VASc scores <5, the patients with CHA₂DS₂-VASc scores ≥5 had higher risk of death (HR: 2.01, 95% CI: 1.65–2.45, \( P < 0.001 \)). Multivariable Cox regression analysis demonstrated that CHA₂DS₂-VASc score ≥5 could independently predict mortality with the adjustment of the risk variables not included in the CHA₂DS₂-VASc score (adjusted HR: 1.78, 95% CI: 1.45–2.18, \( P < 0.001 \)) (Table 2). Moreover, all types of HF could significantly predict the risk of death, with HFrEF contributing the most (adjusted HR for HFrEF: 2.06, 95%CI: 1.52–2.79, \( P < 0.001 \)); for HFmrEF: 1.74, 95% CI: 1.24–2.45, \( P = 0.001 \); for HFpEF: 1.38, 95% CI: 1.13–1.69, \( P = 0.002 \), respectively).
Prediction of the CHA$_2$DS$_2$-VASc Score for Mortality

In elderly patients with CAD and AF, CHA$_2$DS$_2$-VASc $\geq$5 had a modest predictive ability for all-cause death in-hospital (C-index = 0.66, 95% CI: 0.62–0.69, $P < 0.001$), during 1-year (C-index = 0.65, 95% CI: 0.63–0.67, $P < 0.001$), and 5-year (C-index = 0.60, 95% CI: 0.59–0.61, $P < 0.001$) follow-ups. The diagnostic statistics for the CHA$_2$DS$_2$-VASc
TABLE 2 | Predictors of mortality in elderly patients with CAD and AF by Cox regression analysis.

| Variables            | Univariate analysis |         |         | Multivariate analysis |         |         |
|----------------------|---------------------|---------|---------|-----------------------|---------|---------|
|                      | HR                  | 95% CI  | P       | HR                    | 95% CI  | P       |
| Age                  | 1.09                | 1.07–1.10 | <0.001 | 1.08                  | 1.06–1.09 | <0.001 |
| *BMI<18.5            | 1.84                | 1.34–2.51 | <0.001 | 1.72                  | 1.25–2.35 | 0.001   |
| *BMI>30              | 0.89                | 0.63–1.24 | 0.486  | 1.01                  | 0.73–1.41 | 0.936   |
| Previous AMI         | 1.62                | 1.31–1.99 | <0.001 | 1.33                  | 1.08–1.65 | 0.008   |
| AMI                  | 2.44                | 1.90–3.13 | <0.001 | 2.08                  | 1.62–2.67 | <0.001 |
| HF                   | 2.30                | 1.95–2.71 | <0.001 | 1.42                  | 1.18–1.72 | <0.001 |
| HFpEF                | 2.29                | 1.78–2.94 | <0.001 | 2.06                  | 1.52–2.79 | <0.001 |
| HFmrEF               | 2.13                | 1.57–2.89 | <0.001 | 1.74                  | 1.24–2.45 | 0.001   |
| Diabetes             | 1.27                | 1.07–1.51 | 0.006  | 1.11                  | 0.92–1.33 | 0.296   |
| Prior TIA/Stroke     | 1.28                | 1.08–1.52 | 0.005  | 1.05                  | 0.90–1.14 | 0.487   |
| PAD                  | 1.90                | 1.59–2.64 | <0.001 | 1.03                  | 0.81–1.28 | 0.351   |
| CKD                  | 2.03                | 1.63–2.54 | <0.001 | 2.04                  | 1.42–2.94 | <0.001 |
| COPD                 | 1.87                | 1.30–2.69 | 0.001  | 1.78                  | 1.43–2.23 | <0.001 |
| Malignancy           | 1.69                | 1.36–2.09 | <0.001 | 1.49                  | 1.20–1.85 | <0.001 |
| CHA2DS2-VASc Score ≤5| 1.0 (Reference)    | 1.0 (Reference) |       | 1.78                  | 1.45–2.18 | <0.001 |
| CHA2DS2-VASc Score >5| 2.01                | 1.65–2.45 | <0.001 | 1.78                  | 1.45–2.18 | <0.001 |

*Compared to the reference value of BMI 22 kg/m². †Adjusted by the risk factors with a statistically significant P-value <0.05 after the univariate analysis. ‡Adjusted by the risk factors not included in the CHA2DS2-VASc score with a statistically significant P-value <0.05 after the univariate analysis. CI, Confidence interval; BMI, Body mass index; AMI, Acute myocardial infarction; HF, Heart failure; HFpEF, Heart failure with reduced ejection fraction; HFmrEF, Heart failure with mid-range ejection fraction; HFpEF, Heart failure with preserved ejection fraction; AF, Atrial fibrillation; TIA, Transient ischemic attack; PAD, Peripheral arterial disease; CKD, Chronic kidney disease; COPD, Chronic obstructive pulmonary disease.

TABLE 3 | Statistics of the CHA2DS2-VASc Score for the prediction of death.

| CHA2DS2-VASc score ≥5 | HL-p | C-index (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|------------------------|------|------------------|----------------------|----------------------|--------------|--------------|
| All death              | 0.28 | 0.60 (0.59–0.61) | 52.6 (48.4–56.7)     | 67.1 (64.1–70.0)     | 48.3 (44.4–52.2) | 70.8 (67.8–73.7) |
| In SCAD                | 0.86 | 0.59 (0.57–0.60) | 48.2 (42.4–54.0)     | 68.5 (64.4–72.3)     | 45.0 (39.5–50.6) | 71.1 (67.1–74.9) |
| In ACS                 | 0.94 | 0.61 (0.60–0.63) | 57.2 (51.2–63.0)     | 65.4 (60.7–70.0)     | 51.6 (45.9–57.2) | 70.3 (65.6–74.7) |
| In hospital death      | 0.57 | 0.66 (0.62–0.69) | 70.8 (55.7–82.6)     | 58.1 (55.5–60.5)     | 5.0 (3.8–7.0)   | 98.4 (97.3–99.1) |
| In SCAD                | 0.65 | 0.63 (0.58–0.68) | 62.5 (40.8–80.4)     | 63.4 (60.0–66.6)     | 4.7 (2.7–7.8)   | 98.3 (96.7–99.2) |
| In ACS                 | 0.93 | 0.68 (0.64–0.73) | 79.2 (57.3–92.1)     | 57.7 (54.0–61.4)     | 6.1 (3.8–9.4)   | 98.8 (97.0–99.5) |
| 1-year death           | 0.97 | 0.65 (0.63–0.67) | 68.1 (59.6–75.6)     | 59.6 (57.0–62.2)     | 13.9 (11.5–16.8) | 95.1 (93.4–96.4) |
| In SCAD                | 0.57 | 0.62 (0.58–0.65) | 59.4 (46.4–71.2)     | 64.4 (61.0–67.8)     | 11.9 (8.6–16.1) | 95.2 (92.9–96.8) |
| In ACS                 | 0.11 | 0.67 (0.64–0.70) | 75.3 (63.6–84.4)     | 60.1 (56.2–63.9)     | 17.5 (13.6–22.3) | 95.6 (93.0–97.3) |
| 5-year death           | 0.51 | 0.60 (0.59–0.61) | 57.0 (51.9–62.0)     | 60.0 (56.0–63.9)     | 47.4 (42.8–52.1) | 68.8 (64.6–72.7) |
| In SCAD                | 0.29 | 0.58 (0.57–0.60) | 51.1 (43.7–58.3)     | 66.6 (62.8–70.1)     | 30.3 (25.4–35.7) | 82.7 (79.2–85.7) |
| In ACS                 | 0.52 | 0.61 (0.60–0.63) | 60.7 (53.5–67.5)     | 62.9 (58.6–67.0)     | 37.9 (32.6–43.5) | 81.1 (76.9–84.7) |

HL-p, Hosmer–Lemeshow goodness-of-fit test p-value; C-index, Concordance index; CI, Confidence interval; SCAD, Stable coronary artery disease; ACS, Acute coronary artery disease; PPV, Positive predictive value; NPV, Negative predictive value; CAD, Coronary heart disease; AF, Atrial fibrillation.

DISCUSSION

In this cohort study, the main findings were that (1) the CHA2DS2-VASc score was a significant predictor of death in elderly patients with CAD and AF, and the mortality generally increased with the increasing CHA2DS2-VASc score, exhibiting a clear dose-response relationship; (2) CHA2DS2-VASc score independently and strongly predicted the in-hospital, 1- and 5-year death in elderly patients with CAD and AF, and the mortality generally increased with the CHA2DS2-VASc score, exhibiting a clear dose-response relationship; (3) CHA2DS2-VASc score was a significant predictor of death in elderly patients with CAD and AF, and the mortality generally increased with the increasing CHA2DS2-VASc score, exhibiting a clear dose-response relationship; (4) CHA2DS2-VASc score was a significant predictor of death in elderly patients with CAD and AF, and the mortality generally increased with the increasing CHA2DS2-VASc score, exhibiting a clear dose-response relationship.
5-year death in elderly patients with CAD and AF. To our knowledge, this is the first study to evaluate the predictive ability of the CHA₂DS₂-VASc score for death in elderly patients with CAD and AF. This study could facilitate risk stratification and improve the prevention of death associated with comorbid CAD and AF in elderly patients.

AF is the most common arrhythmia, with high incidence and prevalence, and is associated with an increased risk of all-cause death and stroke (30, 31). CAD, especially AMI, will also lead to other complications and increase the risk of death (32). Age is an obvious risk factor for patients with CAD and AF (31, 33), and elderly individuals are more likely to have coexisting CAD and AF, thus the risk of death in elderly patients with CAD and AF is higher. In addition to the assessment of thromboembolic risk in patients with AF, the CHA₂DS₂-VASc score has been shown to predict the adverse outcomes for other cardiovascular conditions, such as chest pain (25), ACS (21, 22), AMI (24), HF (20), pulmonary emboli (23), and ACS undergoing percutaneous coronary intervention (PCI) (26). Therefore, we believe that the CHA₂DS₂-VASc score is a feasible predictor of prognosis in elderly patients with CAD and AF. The sensitivity of the CHA₂DS₂-VASc score was higher than specificity for the prediction of death in-hospital or within 1-year. It indicated that the CHA₂DS₂-VASc score could effectively evaluate the mortality of elderly patients with CAD and AF in-hospital or within 1 year follow-up in the study. When the CHA₂DS₂-VASc score is ≥5, the probability of death within 1 year will increase significantly. Additionally, with the increase in the CHA₂DS₂-VASc score, the in-hospital, 1- and 5-year mortality also increased. These results indicate that the CHA₂DS₂-VASc score could predict the prognosis of elderly patients with CAD and AF.

The risk factors for death in elderly patients with CAD and AF were assessed for the first time in this cohort. We found that in addition to the CHA₂DS₂-VASc score, the independent risk factors for all-cause death in elderly patients with CAD and AF included BMI <18.5 kg/m², previous or current AMI, CKD, COPD, and malignancy. Similar risk factors for death were also found in AF patients in the ROCKET-AF study (34) and the GARFIELD-AF global prospective registry (35), suggesting that overall mortality due to AF is tightly linked to the same risk factors and comorbidities. Our results also emphasized the prognostic importance of underweight (BMI <18.5 kg/m²) in the elderly population. We found that BMI <18.5 kg/m² was a significant predictor of overall mortality, which probably reflects the known association between a decrease in BMI and an increase in mortality in CAD patients, regardless of the baseline BMI value (36). Further studies are needed to better understand the impact of the combination of risk factors on mortality in the elderly population.

The combination of AF and CAD is a common and complex clinical condition in which to address anticoagulation therapy (37), especially in elderly patients. Taking OACs can reduce the risk of embolism, but it also increases the risk of bleeding. Therefore, whether to take OACs should be judged by the patient’s health situation (38). If AF develops during the first year after ACS and there is an indication for thromboembolic prevention with anticoagulation, OACs should be started. In stable CAD patients with AF, oral anticoagulation is necessary when the CHA₂DS₂-VASc score is ≥2 (39). Elderly patients requiring anticoagulation for AF are at higher risk of adverse outcomes, but also have a higher absolute benefit from OAC (40). However, in our study, the application rate of OACs was only 27.1%, and it did not increase with the CHA₂DS₂-VASc score, suggesting that the application of OACs in elderly patients with CAD and AF was not sufficient, which might attribute to the increasing risk of death in patients with higher value of CHA₂DS₂-VASc score. Previous studies have found that the application of OACs in the elderly population was insufficient (41). Therefore, the use of OACs in elderly patients with CAD and AF should be increased, and further studies are needed to verify whether the application of OAC could decrease the mortality in these patients.

Several limitations of this study warrant consideration. The present study was an observational real-world study in which we did not exclude severely ill patients (who are typically excluded from clinical trials), thus, the mortality in elderly patients with CAD and AF might be higher than expected in clinical trials. Data on the clinical parameters and drug therapies were obtained from electronic health record. Although the data was validated and found to be highly accurate, not all clinical characteristics could be verified. While we tried to make adjustment for the clinically relevant parameters, it is impossible to adjust for all variables that may affect the outcomes. In addition, the study was based on a single-center cohort, and the findings should be validated in large multicenter cohorts.

CONCLUSION

The CHA₂DS₂-VASc score could independently predict all-cause death in the elderly patients with concomitant CAD and AF.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Ethics Committee of the General Hospital of the People’s Liberation Army. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

TY, JM, and YZha: study concept and design. YW, JL, LD, LQ, HY, WG, XF, GW, ZW, RD, and YZou: acquisition of data. GW, YW, LQ, LD, and TY: analysis and interpretation of data.
GW,YW,LD,LQ,andTY: drafting of the manuscript. TYandJM: critical revision of the manuscript for important intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by grants from the National Natural Science Foundation of China (Nos. 81870262 and 82170352).

REFERENCES

1. Michniewicz E, Mlodawska E, Lopotowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - double trouble. Adv Med Sci. (2018) 63:30–5. doi: 10.1016/j.admsci.2017.06.005

2. Madhavan MV, Gersh BJ, Alexander KP, Granger CB, Stone GW. coronary artery disease in patients >/=80 years of age. J Am Coll Cardiol. (2018) 71:2015–40. doi: 10.1016/j.jacc.2017.12.068

3. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. (2021) 42:373–98. doi: 10.1093/eurheartj/ehaa612

4. Wang J, Yang YM, Zhu J. Mechanisms of new-onset atrial fibrillation. Herz. (2015) 1(Suppl. 40):18–26. doi: 10.1007/s00059-014-4149-3

5. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation. (2017) 135:e146–603. doi: 10.1161/CIR.0000000000000485

6. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACC/PCNA/SCAI/STS guide for the diagnosis management of atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. (2012) 60:e44–164. doi: 10.1016/j.jacc.2012.07.013

7. Fihn SD, Blankenship JC, Alexander KP, Butzl JA, Byrne JG, Fletcher BJ, et al. 2014 ACCF/AHA/ACCP/PCNA/SCAI/STS guide for the diagnosis management of patients with stable ischemic heart disease: a report of the American college of cardiology/American heart association task force on practice guidelines, and the American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. (2012) 60:e44–49. doi: 10.1016/j.jacc.2014.07.017

8. Dai X, Busby-Whitehead J, Forman DE, Alexander KP. Stable ischemic heart disease in the older adults. J Geriatr Cardiol. (2016) 13:109–14. doi: 10.1016/j.jgc.2016.02.013

9. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. (2016) 387:1057–65. doi: 10.1016/S0140-6736(15)01166-6

10. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/flutter following acute myocardial infarction. TRACE study group. TRAndolapril cardiac evaulation. Eur Heart J. (1999) 20:748–54. doi: 10.1093/eurhj/99.13.1352

11. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. (2000) 101:969– 74. doi: 10.1161/01.CIR.101.9.969

12. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. (2008) 94:867–73. doi: 10.1136/hrt.2007.134486

13. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. (2009) 30:1038– 45. doi: 10.1093/eurheartj/ehn579

14. Chugh SS, Havmoeller R, Narayanani K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. (2014) 129:837–47. doi: 10.1161/CIRCULATIONAHA.113.05119

15. Kundu A, O’Day K, Shaikh AY, Lessard DM, Szczyński JS, Zarzeński J, et al. Relation of atrial fibrillation in acute myocardial infarction to in-hospital complications and early hospital readmission. Am J Cardiol. (2016) 117:1213– 8. doi: 10.1016/j.amjcard.2016.01.012

16. Wi J, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, et al. Transient new-onset atrial fibrillation is associated with poor clinical outcomes in patients with acute myocardial infarction. Circ. (2016) 80:1615– 23. doi: 10.1016/j.circj.15-1230

17. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global utilization of streptokinase and TPA for occluded coronary arteries. J Am Coll Cardiol. (1997) 30:406– 13. doi: 10.1016/S0735-8796(97)00194-0

18. Stenestrand U, Lindback J, Wallentin L, Registry, R.-H. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the register of information and knowledge about swedish heart intensive care admissions (RIKS-HIA). Circulation. (2005) 112:3225– 31. doi: 10.1161/CIRCULATIONAHA.105.552984

19. Mehta RH, Daboush OH, Granger CB, Kuznetsova P, Kline-Rogers EM, Anderson Jr A, et al. Comparison of outcomes of patients with acute coronary syndromes and with atrial fibrillation. J Am Coll Cardiol. (2003) 92:1031– 6. doi: 10.1016/j.jacc.2003.06.001

20. Shuvy M, Zwas DR, Keren A, Gotsman I. Value of the CHA2DS2-VASc score for predicting outcome in patients with heart failure. ESC Heart Fail. (2020) 7:2533–60. doi: 10.1002/ehf2.12831

21. Chua SK, Lo HM, Chiu CZ, Shyu KG. Use of CHADS2 and CHA2DS2-VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry. PLoS One. (2014) 9:e111167. doi: 10.1371/journal.pone.0111167

22. Rozenbaum Z, Ellis A, Shuvy M, Vorobiechik D, Shlomo N, Shlezingier M, et al. CHA2DS2-VASc score and clinical outcomes of patients with acute coronary syndrome. Euro J Intern Med. (2016) 36:57–61. doi: 10.1016/j.ejim.2016.09.010

23. Gok M, Kurtul A, Harman M, Kara M, Suleymanoglu M, Ornek E. Relationship between CHA2DS2-VASc score right ventricular dysfunction in patients with acute pulmonary thromboembolism. Clin Appl Thromb Hemost. (2018) 24(Suppl. 9):S65-625. doi: 10.1177/1076029618587711

24. Li CY, Chung CJ, Chung WJ, Lin CJ, Hsueth SK, Lee CH, et al. Assessment of CHA2DS2-VASc score for predicting cardiovascular and cerebrovascular outcomes in acute myocardial infarction patients. Medicine. (2018) 97:e11230. doi: 10.1097/MD.0000000000011230

25. Topaz G, Haisraely O, Shacham Y, Beery G, Shilo L, Kassem N, et al. CHA2DS2 -VASc score and clinical outcomes of patients with chest pain discharged from internal medicine wards following acute coronary syndrome rule-out. Clin Cardiol. (2018) 41:539–43. doi: 10.1002/clc.22925

26. Ma X, Shao Q, Dong L, Cheng Y, Lv S, Shen H, et al. Prognostic value of CHA2DS2 and CHA2DS2-VASc scores for post-discharge outcomes in patients with acute coronary syndrome.
undergoing percutaneous coronary intervention. *Medicine.* (2020) 99:e21321. doi: 10.1097/MD.0000000000021321

27. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med.* (2010) 363:2211–9. doi: 10.1056/NEJMoa1003367

28. European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). *Eur Heart J.* (2010) 31:2369–429. doi: 10.1093/eurheartj/ehq278

29. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland Jr C, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. *Circulation.* (2019) 140:e125–51. doi: 10.1161/CIR.0000000000006665

30. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. *European.* (2013) 15:486–93. doi: 10.1093/europace/eus333

31. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ.* (2016) 354:i4482. doi: 10.1136/bmj.i4482

32. Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. *Adv Exp Med Biol.* (2020) 1177:1–36. doi: 10.1007/978-981-15-2517-9_1

33. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. *J Cell Physiol.* (2019) 234:16812–823. doi: 10.1002/jcp.28350

34. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. *J Am Heart Assoc.* (2016) 5:e002197. doi: 10.1161/JAHA.115.002197

35. Gibbs H, Freedman B, Rosenqvist M, Virdone S, Mahmoud WA, Ambrozio G, et al. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: implications for AF screening. *Am J Med.* (2021) 134 893–901 e811. doi: 10.1016/j.amjmed.2021.01.017

36. Dong SY, Yan ST, Wang ML, Li ZB, Fang LQ, Zeng Q. Associations of body weight and weight change with cardiovascular events and mortality in patients with coronary heart disease. *Atherosclerosis.* (2018) 274:104–11. doi: 10.1016/j.atherosclerosis.2018.05.007

37. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J.* (2018) 39:1330–93. doi: 10.1093/eurheartj/ehy136

38. Wojszel ZB. Dementia diagnoses and treatment in geriatric ward patients: a cross-sectional study in poland. *Clin Interv Aging.* (2020) 15:2183–94. doi: 10.2147/CIA.S281723

39. Verheugt FWA, Ten Berg JM, Storey RF, Cusset T, Granger CB. Antithrombotics: from aspirin to DOACs in coronary artery disease and atrial fibrillation (Part 3/5). *J Am Coll Cardiol.* (2019) 74:699–711. doi: 10.1016/j.jacc.2019.02.080

40. Bauersachs RM, Herold J. Oral anticoagulation in the elderly and frail. *Hamostaseologie.* (2020) 40:74–83. doi: 10.1055/s-0040-1701476

41. Dregan A, Ravindrarajah R, Charlton J, Ashworth M, Molokhia M. Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. *Ann Epidemiol.* (2018) 28:440–6. doi: 10.1016/j.annepidem.2018.03.006

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wu, Wang, Dong, Qin, Li, Yan, Guo, Feng, Zou, Wang, Du, Zhang, Ma and Yin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.